nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

09.05.2022 | case report

Neurotoxicity as a rare side effect of immune checkpoint inhibitors. A case report and review of the literature

verfasst von: Simon Udovica, Kathrin Strasser-Weippl, Eva Fischer, Dora Niedersüß-Beke

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Summary

Neurotoxicity is a rare but often fatal immune-related adverse event (irAE). Here we report the case of a 73-year-old woman treated with pembrolizumab for metastatic bladder cancer who developed aseptic meningoencephalitis after two courses of immunotherapy. Cranial magnetic resonance imaging (cMRI) showed disseminated dot-like lesions in the terminal vascular bed of both hemispheres suggesting aseptic meningitis or vasculitis. No infectious cause could be identified in cerebrospinal fluid (CSF) cultures and polymerase chain reaction (PCR) analyses. She was treated with high-dose steroids and pre-emptive antiviral/antibiotic therapy. The patient died 6 days after onset of symptoms.

Vorheriger Artikel Cardiopulmonary sequelae of COVID-19

Nächster Artikel Immunotherapy pitfall: sarcoid-like reaction mimicking disease progression in advanced melanoma treated with nivolumab

Thompson JA. New NCCN guidelines: Recognition and management of immunotherapy-related toxicity. J Natl Compr Canc Netw. 2018;16(5S):594–6. https://doi.org/10.6004/JNCCN.2018.0047.CrossRefPubMed

Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104. https://doi.org/10.3322/caac.21596.CrossRefPubMed

Cuzzubbo S, et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer. 2017;73:1–8. https://doi.org/10.1016/J.EJCA.2016.12.001.CrossRefPubMed

Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021; https://doi.org/10.1200/JCO.21.01440.CrossRefPubMed

Wang DY, et al. Fatal toxic effects associated with immune checkpointinhibitors: A systematic review and meta-analysis. JAMA Oncol. 1721;4:12. https://doi.org/10.1001/JAMAONCOL.2018.3923.

Lakeman FD, et al. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1995;171(4):857–63. https://doi.org/10.1093/INFDIS/171.4.857.CrossRefPubMed

Velasco R, et al. Encephalitis induced by immune checkpoint inhibitors: A systematic review. JAMA Neurol. 2021;78(7):864–73. https://doi.org/10.1001/JAMANEUROL.2021.0249.CrossRefPubMed

Johnson DB, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019;7:1. https://doi.org/10.1186/S40425-019-0617-X.CrossRef

Galmiche S, et al. Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: A monocentric retrospective study. J Eur Acad Dermatol Venereol. 2019;33(12):e440–e3. https://doi.org/10.1111/JDV.15756.CrossRefPubMed

10.

Larkin J, et al. Neurologic serious adverse events associated with Nivolumab plus Ipilimumab or Nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22(6):709. https://doi.org/10.1634/THEONCOLOGIST.2016-0487.CrossRefPubMedPubMedCentral

Titel: Neurotoxicity as a rare side effect of immune checkpoint inhibitors. A case report and review of the literature
verfasst von: Simon Udovica
Kathrin Strasser-Weippl
Eva Fischer
Dora Niedersüß-Beke
Publikationsdatum: 09.05.2022
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-022-00805-w

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Renal cell carcinoma—presentation highlights from the ESMO Congress 2021

COVID-19 crisis and cancer

New targeted therapies/small molecules in oncology and hematology

Agony of choice—selecting chronic lymphocytic leukemia treatment in 2022

Tracking mutation and drug-driven alterations of oncokinase conformations

COVID-19: New disease mechanism is simultaneously a therapeutic target